Open-Label Extension of Other SZ1839 (Iressa) Trials

AstraZeneca100 enrolled

Overview

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Cancer

Interventions

Gefitinib (Iressa)DRUG

Iressa

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Received treatment in a previous Iressa clinical trial * Provided Informed Consent to participate in the trial * 30 days or less since completing the previous Iressa trial. Exclusion Criteria: * Radiotherapy completed more than 14 days before starting treatment in this trial * Incomplete healing from prior surgery * Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

Outcomes

Primary Outcomes

Adverse Events

Time frame: Every 28 days

Secondary Outcomes

Progression Free Survival

Time frame: Every 28 days

Survival

Time frame: Every 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.